ReviewBioMed research international2013
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer?
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 109 citations in OpenAlex.
- The effect of thunder-fire moxibustion on cancer-related fatigue in patients with Qi stagnation and blood stasis type colorectal cancer undergoing chemotherapy: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Adjunctive photodynamic therapy improves outcomes and quality of life in condyloma acuminatum after radical cervical cancer surgery.Frontiers in oncology · 2026Article
- Specific inhibitor to KRASJournal for immunotherapy of cancer · 2025Article
- Antitumor immunostimulatory effect via cell-killing action of a novel extracorporeal blood circulating photodynamic therapy system using 5-aminolevulinic acid.Scientific reports · 2025Article
- Shifting cold to hot tumors by nanoparticle-loaded drugs and products.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Immunogenic cell death-related genes as prognostic biomarkers and therapeutic insights in uterine corpus endometrial carcinoma: an integrative bioinformatics analysis.Frontiers in oncology · 2025Article
- Overcoming resistant cancerous tumors through combined photodynamic and immunotherapy (photoimmunotherapy).Frontiers in immunology · 2025Review
- Nickel(II) Phototheranostics: A Case Study in Photoactivated HJournal of the American Chemical Society · 2023Article
- The use of nanomaterials in advancing photodynamic therapy (PDT) for deep-seated tumors and synergy with radiotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Recent advances in noble metal complex based photodynamic therapy.Chemical science · 2022Review
- Photodynamic therapy using mannose-conjugated chlorin e6 increases cell surface calreticulin in cancer cells and promotes macrophage phagocytosis.Medical oncology (Northwood, London, England) · 2022Article
- Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.BMC medicine · 2022Article
- Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.American journal of cancer research · 2022Article
- Photodynamic Therapy: A Compendium of Latest Reviews.Cancers · 2021Review
- Low Dose Soft X-Ray Remotely Triggered Lanthanide Nanovaccine for Deep Tissue CO Gas Release and Activation of Systemic Anti-Tumor Immunoresponse.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.Cancer immunology research · 2021Article
- Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.Oncology reports · 2021Article
- Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death.Scientific reports · 2021Article
- Potential of Photodynamic Therapy Based on Sugar-Conjugated Photosensitizers.Journal of clinical medicine · 2021Review
- Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunogenic Cell Death (ICD) could represent the keystone in cancer management since tumor cell death induction is crucial as well as the control of cancer cells revival after neoplastic treatment. In this context, the immune system plays a fundamental role. The concept of Damage-Associated Molecular Patterns (DAMPs) has been proposed to explain the immunogenic potential of stressed or dying/dead cells. ICD relies on DAMPs released by or exposed on dying cells. Once released, DAMPs are sensed by immune cells, in particular Dendritic Cells (DCs), acting as activators of Antigen-Presenting Cells (APCs), that in turn stimulate both innate and adaptive immunity. On the other hand, by exposing DAMPs, dying cancer cells change their surface composition, recently indicated as vital for the stimulation of the host immune system and the control of residual ill cells. It is well established that PhotoDynamic Therapy (PDT) for cancer treatment ignites the immune system to elicit a specific antitumor immunity, probably linked to its ability in inducing exposure/release of certain DAMPs, as recently suggested. In the present paper, we discuss the DAMPs associated with PDT and their role in the crossroad between cancer cell death and immunogenicity in PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.